Experimental virus therapy enters human testing for tough cancers
NCT ID NCT04735978
First seen Sep 30, 2025 · Last updated Apr 20, 2026 · Updated 20 times
Summary
This early-stage study is testing a modified virus called RP3, both alone and combined with an existing immunotherapy drug, in people with advanced solid tumors that haven't responded to standard treatments. The main goals are to find the safest dose and understand the side effects. The study involves 123 adults and is the first step to see if this approach is safe enough for larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital
Oxford, OX3 9DU, United Kingdom
-
Hospital Clinic Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy
Villejuif, 94805, France
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3
Madrid, 28050, Spain
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Merseyside, CH63 4JY, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University General Hospital Attikon
Athens, 12462, Greece
-
University of Athens
Athens, 11527, Greece
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital)
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.